Optimizing Treatment Outcomes in Advanced NSCLC with Concurrent Biomarker Testing - Episode 7

Challenges of NSCLC Biomarker Testing in Clinical Practice

,

Zofia Piotrowska, MD, MHS, shares insights into the challenges and advantages of diagnostic testing practices at Massachusetts General Hospital, including the benefits of on-site testing, the need for less streamlined consent forms, and areas for improvement to expedite the diagnostic testing ordering process.

EP. 1: Optimizing NSCLC Patient Outcomes Through Concurrent Biomarker Testing
EP. 2: Concurrent NSCLC Biomarker Testing at Diagnosis
EP. 3: NCCN Guidelines: Optimizing NSCLC Treatment with Concurrent Biomarker Testing
EP. 4: Improving Time-to-Treatment for Patients With Non-Small Cell Lung Cancer
EP. 5: Biomarker Testing in Early-Stage NSCLC
EP. 6: Reflex Testing for Patients with Suspected Lung Cancer
Now Viewing
EP. 7: Challenges of NSCLC Biomarker Testing in Clinical Practice
EP. 8: Overcoming Barriers to NSCLC Biomarker Testing
EP. 9: Key Takeaways for Concurrent Biomarker Testing in NSCLC

Related Content:

Optimizing Treatment Outcomes in Advanced NSCLC with Concurrent Biomarker TestingThe US Oncology NetworkLung CancerOncLive News Network®
China’s NMPA Approves First-Line Osimertinib Plus Chemotherapy in EGFR-Mutant NSCLC
ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC
Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer